Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL OILY versus OXILAN 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL OILY versus OXILAN 300.
DIONOSIL OILY vs OXILAN-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL OILY is a radiographic contrast agent containing propyliodone, which is an iodine-containing compound that absorbs X-rays, thereby enhancing the visualization of body structures during imaging procedures.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
Adults: 10 mL intraurethral instillation as a sterile oily suspension (50% w/v) once daily for 3-5 days.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
None Documented
None Documented
Terminal elimination half-life of the iodine moiety is approximately 60 days due to slow release from fatty tissues. This long half-life reflects the persistence of the oily vehicle and slow deiodination, necessitating monitoring for cumulative iodine effects.
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Primarily renal excretion of the water-soluble metabolite (propiodone) after hepatic deiodination; approximately 60-80% of the administered iodine is excreted in urine within 48 hours. Fecal excretion is negligible (<5%).
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent